Navigation Links
OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
Date:11/19/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 19, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the SYNERGY trial is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC).

The primary registration Phase 3 SYNERGY trial is designed to evaluate a survival benefit for custirsen in combination with first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC). Approximately 1,023 men have been enrolled to SYNERGY at 140 sites primarily in North America and Europe. SYNERGY completed enrollment in 2012 and final survival results are expected to be announced by mid-2014.

"The recommendation for SYNERGY to continue to final analysis is not surprising as the criteria to achieve statistical significance on the interim are considerably more stringent than the criteria required for the final analysis," stated Scott Cormack, President and CEO of OncoGenex.  "We do not believe these results can be interpreted to predict the final outcome of SYNERGY and we eagerly anticipate the reporting of final survival results next year."

OncoGenex and custirsen co-development and commercialization partner, Teva Pharmaceutical Industries, Ltd., continue to remain blinded to all SYNERGY data and analyses, including details regarding survival and statistical evaluations. The IDMC also remains blinded to the details of the interim efficacy data and analyses.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer.  Apatorsen is currently being evaluated in seven randomized Phase 2 trials for a variety of cancers and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company's Twitter account: https://twitter.com/OncoGenex_IR.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and reporting of results and statements regarding the potential benefits and potential development of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product candidates and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended September, 2013. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
3. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
4. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
5. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
6. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
7. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
9. Assured Pharmacy, Inc. Announces Extension of Issuer Tender Offer
10. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
11. International Isotopes Inc. Announces Third Quarter And Nine Months 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
(Date:9/7/2017)...  Eli Lilly and Company (NYSE: ... to more efficiently focus resources on developing new ... workforce reductions, including those from a U.S. voluntary ... 3,500 positions. With the streamlining ... approximately $500 million that will begin to be ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... 2017 , ... After a summer-long contest to crown the ... Drivers proudly announced the winners of the HEROtini Mocktail Challenge at the Stockton ... the challenge of competing in three categories: Best HEROtini Mocktail, Top HEROtini Bartender, ...
(Date:9/26/2017)... ... , ... Data Integrity: , The Key to FDA and GMP Compliance, ** ... http://www.fdanews.com/fdadataintegrity , Consider this situation. The FDA gives simple ... be trustworthy and reliable … a more detailed evaluation may be warranted.” , ...
(Date:9/26/2017)... ... 26, 2017 , ... Dr. Kovatis, is a Hospital for ... and Foot Section of the Department of Orthopedic Surgery at Hackensack University Medical ... UMC performing total ankle replacements. Because of this, Dr. Kovatis is often referred ...
(Date:9/26/2017)... , ... September 26, 2017 , ... The 2017 American ... called “The Magic of Fat,” revealed not only the latest about cosmetic procedures to ... be an evolution in cosmetic medicine. , “Fat really is magical, especially when it ...
(Date:9/26/2017)... ... 26, 2017 , ... The Organizing Committee is pleased to ... Pittcon 2018. As of July 1, Adrian C. Michael, Ph.D. (University of Pittsburgh, ... Charles Gardner, (ChemImage Corporation) and selected chairs. , Other members of ...
Breaking Medicine News(10 mins):